 | |
- close
- close
|
RELATED WIKI ARTICLES
Enzon to Release Third Quarter 2009 Earnings on Tuesday, November 3, 2009; Conference Call and Webcast to Follow
Business Wire
Oct 28, 2009
Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN) announced today that it will report its financial results for the quarter ended September 30, 2009, on Tuesday, November 3, 2009 at approximately 8:00 am Eastern Time (ET). The release will be followed by a live conference call, which will begin at approximately 10:00 am Eastern Time (ET) on Tuesday, November 3, 2009.
Participating in the call from Enzon’s executive management team will be Jeffrey H. Buchalter, President and Chief Executive Officer, and Craig Tooman, Executive Vice President, Finance and Chief Financial Officer.
All interested parties may access the call by using the following information:
| Domestic Dial-In Number: | (877) 397-0272 | ||||
| International Dial-In Number: | (719) 325-4861 | ||||
| Access Code: | Enzon |
The call will also be available via live audio webcast at the following site: http://investor.enzon.com/eventdetail.cfm?eventid=74303. Listeners should go to the website at least fifteen minutes before this event to download and install any necessary audio software. For those unable to attend the live audio webcast, a replay will be available beginning approximately one hour after the event. Additionally, a telephonic rebroadcast will also be available following the call. The rebroadcast will begin on Tuesday, November 3, 2009 at approximately 1:00 pm Eastern Time (ET) and end on Tuesday, November 10, 2009 at approximately 12:00 am Eastern Time (ET). It may be accessed using the following information:
| Domestic Dial-In Number: | (888) 203-1112 | ||||
| International Dial-In Number: | (719) 457-0820 | ||||
| Replay Passcode: | 6129874 |
About Enzon
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. The Company has a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Enzon’s drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform and the Locked Nucleic Acid (LNA) technology. Enzon’s PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden its revenue base. Further information about Enzon and this press release can be found on the Company’s web site at www.enzon.com.
(c) 2009 Business Wire, Inc., All rights reserved. All of the news releases and other content contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. Any copying or reproduction (other than for an individual user's personal reference), redistribution, reposting or other transmission or communication is expressly prohibited without prior written permission of Business Wire, Inc
| ||||||
Wikinvest © 2006, 2007, 2008, 2009. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
|
|
